WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
RALEIGH, N.C., Feb. 04, 2016 -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2015 results after the market closes on Wednesday, February 24, 2016. The Company will also host a conference call on Thursday, February 25, 2016 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 46737204. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 46737204.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, the presentation and an audio playback of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. As a top five CRO, PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.
INVESTOR INQUIRIES: [email protected] INQUIRIES: Christine Rogers, Manager – Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +919.786.8463
